Neumora Therapeutics Stock Plunges 50% After Phase 3 KOASTAL Study Fails, 35% Workforce Cut

The Quick Take

• Neumora Therapeutics (NMRA) stock plunged approximately 50% after the company announced the discontinuation of its Phase 3 KOASTAL study of navacaprant.
• The failed Phase 3 trial will be accompanied by a 35% workforce reduction, reflecting the company's need to preserve cash following the program failure.
• Navacaprant was Neumora's lead asset; its failure removes the company's primary near-term value catalyst and raises pipeline viability concerns.

Neumora Therapeutics' 50% stock decline following the discontinuation of its Phase 3 KOASTAL study of navacaprant represents the archetypal binary event risk in clinical-stage biopharmaceutical investing. Navacaprant, targeting psychiatric indications including major depressive disorder, had been the company's primary asset and the central pillar of its valuation. Phase 3 failure not only eliminates the direct value contribution of this compound but forces a comprehensive reassessment of the company's pipeline, cash runway, and strategic options — all of which are now the dominant variables determining whether any equity value remains.

The accompanying 35% workforce reduction is a rational and expected response to pipeline value destruction: without navacaprant advancing, Neumora's commercialisation infrastructure and the headcount supporting the KOASTAL program are no longer justified by the remaining pipeline's scope. Cash preservation becomes the primary operational mandate for the board, extending the company's runway to explore whether any remaining pipeline assets have sufficient value to attract partnership or acquisition interest. The CNS/psychiatric drug development sector has seen multiple high-profile Phase 3 failures in recent years, underscoring the difficulty of the indication.

Investors and the biotech sector should watch for Neumora's strategic review announcement — whether the company pursues partnership deals for remaining pipeline assets, sells the company in a distressed acquisition, or attempts to restructure around a narrower clinical program. Cash position disclosure at the next interim update will set the timeline for these decisions. The FDA rejection of navacaprant (if applicable) and any post-hoc data analysis that could generate a hypothesis for a reformulated or narrowed patient population study would be the most upside-positive development from the current distressed position.

Synthesized from 1 source.